On September 29, 2016, the pCODR Expert Review Committee (pERC) issued a final recommendation for idelalisib (Zydelig) for follicular lymphoma.
pERC does not recommend reimbursement of idelalisib for the treatment of patients with follicular lymphoma (FL) who have had at least two prior systemic regimens and whose disease is refractory to both rituximab and an alkylating agent. The committee made this recommendation because it was not satisfied that there is a net clinical benefit of idelalisib compared with best supportive care.
You can view the complete report here: https://www.cadth.ca/zydelig-follicular-lymphoma-details
Lymphoma Canada thanks all those who completed surveys or participated in interviews to appeal to the provincial governments to provide funding for this important treatment.
Once Health Canada has approved a cancer drug for use in Canada, the country's provinces and territories must decide if the drug will be eligible for public reimbursement. The CADTH pan-Canadian Oncology Drug Review (pCODR) plays an important role in their decision-making processes.
pCODR conducts thorough and objective evaluations of clinical, economic, and patient evidence on cancer drugs, and uses this evaluation to make recommendations to the provinces and territories in Canada to help them decide whether they will provide funding for new cancer treatments.